The 18th International Conference on Glaucoma & Retinal Diseases will be held on September 24-25, 2018 in Dallas, Texas, USA. The theme of this year's meeting will be:Clinical Glaucoma and Ophthalmic Research. Please see the website for further details on registration, abstract submission and program schedule https://glaucoma.ophthalmologyconferences.com/
The XXII Biennial Meeting of the International Society for Eye Research
champions the advancement of international eye research by uniting the
world's leading clinicians and vision researchers.
This is an exclusive opportunity for experts to share their latest
findings, technical expertise and experiences in the field.
The "WORLD EYE AND VISION CONGRESS" of 2018 will be held at Dubai City, UAE, in September. This year's theme is: Trowel the broadened impacts and front line progressions of Ophthalmology and Vision Science. See website for registration, abstract submission and program schedule: https://eye.conferenceseries.com/
If you or a member of your family has a genetic eye condition caused by changes in the RDH12 gene, you are welcome to attend a patient day organised by Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.
Specialist talks by researchers including:
- Dr Mariya Moosajee
- Mr Rob Henderson
- Dr Adam Dubis
Updates on the latest scientific research, including a new RDH12 specific project
In 2018, the PRO RETINA workgroup will once again organize a seminar for Choroideremia patients and people interested in the disease. The objective of this workgroup is to provide an update on the research and new options regarding the diagnosis and treatment. Initial studies of a gene therapy have already been done worldwide. Gene therapy has already been applied in Germany. We will also report on vision aids and counselling options. This is an excellent opportunity to exchange experiences in dealing with the disease.
MeiraGTx, a London and New York based gene therapy company, announced today the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to MeiraGTx’s gene therapy product candidate A002 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGB3 gene. Achromatopsia is a chronically debilitating inherited eye disorder that severely limits a person’s sight. Patients are legally blind from birth with very poor visual acuity as well as extreme light sensitivity, involuntary eye movement, and complete color blindness.
ViaOpta Hello Application
ViaOpta Hello is a multi-tool application that can assist blind or visually impaired people by using cognitive services and Microsoft latest image analysis technology to identify people, items, and scenes.
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A 12
Foundation Fighting Blindness and ProQR have entered into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program into the clinic. QR-421a received orphan drug designation from the FDA.
The Food and Drug Administration (FDA) in the United States approved the first gene therapy to treat an inherited disease on Tuesday December 19th 2017. Although a gene therapy was approved for an ultra-rare disease in Europe a number of years ago and the FDA approved two gene therapies already this year, one for a form of leukaemia and one for a form of lymphoma, this is the first time such a therapy has been approved for an inherited retinal dystrophy (IRD) and marks a new era of hope for our community as a whole.